1. Signaling Pathways
  2. GPCR/G Protein
    Immunology/Inflammation
  3. CCR
  4. CCR4 Isoform

CCR4

 

CCR4 Related Products (12):

Cat. No. Product Name Effect Purity
  • HY-U00064
    AZD2098
    Inhibitor 99.84%
    AZD2098 is a potent and selective CC-chemokine receptor 4 (CCR4) inhibitor with pIC50s of 7.8, 8.0, 8.0 and 7.6 for human, rat, mouse and dog respectively, used for asthma research.
  • HY-100183
    GSK2239633A
    Antagonist 99.86%
    GSK2239633A is a CC-chemokine receptor 4 (CCR4) antagonist, which inhibits the binding of [125I]-TARC to human CCR4 with a pIC50 of 7.96 ± 0.11.
  • HY-103364
    C-021
    Inhibitor 99.94%
    C-021 is a potent CC chemokine receptor-4 (CCR4) antagonist.
  • HY-103364A
    C-021 dihydrochloride
    Antagonist ≥99.0%
    C-021 dihydrochloride is a potent CC chemokine receptor-4 (CCR4) antagonist.
  • HY-131349
    CCR4-351
    Antagonist 98.02%
    CCR4-351 is an orally active, potent and selective CCR4 antagonist.
  • HY-148074
    Zelnecirnon
    Inhibitor 99.71%
    Zelnecirnon (RPT193) is an orally active inhibitor of CCR4, blocks the recruitment of Th2 inflammatory immune cells into inflamed tissues.
  • HY-P99253
    Mogamulizumab
    Inhibitor
    Mogamulizumab (KW-0761) is a defucosylated humanized recombinant anti-CCR4 monoclonal antibody (MAb).
  • HY-P3982
    CKLF1-C19
    Chemical
    CKLF1-C19 is the C-terminal peptide of human chemokine-like factor 1 (CKLF1).
  • HY-131349A
    CCR4-351 hydrochloride
    Antagonist 98.59%
    CCR4-351 hydrochloride is an orally active, potent and selective CCR4 antagonist.
  • HY-P3418A
    CKLF1-C27 TFA
    Inhibitor
    CKLF1-C27, a C-terminal peptide of CKLF1, binds to CCR4 receptor and activates ERK1/2 pathway.
  • HY-147385
    CCR4 antagonist 3-1
    Antagonist
    CCR4 antagonist 3 is a potent chemokine receptor 4 (CCR4) antagonist with an IC50 value of 1.7 μM for [125I]TARC (thymus and activation regulated chemokine).
  • HY-P3418
    CKLF1-C27
    Inhibitor
    CKLF1-C27, a C-terminal peptide of CKLF1, binds to CCR4 receptor and activates ERK1/2 pathway.